Kadimastem TASE:KDST Stock Report Kadimastem Ltd
TASE:KDST Stock Report
KDST Stock Overview A biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases.
Rewards Risk Analysis + 1 more risk
See All Risk Checks Kadimastem Ltd Competitors Price History & Performance
Summary of all time highs, changes and price drops for Kadimastem Historical stock prices Current Share Price ₪12.16 52 Week High ₪14.20 52 Week Low ₪4.30 Beta 0.47 11 Month Change 74.46% 3 Month Change 112.62% 1 Year Change 109.66% 33 Year Change -70.87% 5 Year Change -79.39% Change since IPO -97.26%
Recent News & Updates
Kadimastem Ltd (TASE:KDST) signed a letter of intent to acquire NLS Pharmaceutics AG (NasdaqCM:NLSP) in a reverse merger transaction. Jul 30
Kadimastem Ltd (TASE:KDST) signed a letter of intent to acquire NLS Pharmaceutics AG (NasdaqCM:NLSP) in a reverse merger transaction. Jul 29 Kadimastem Ltd (TASE:KDST) entered into a non-binding term sheet to acquire IM Cannabis Corp. (CNSX:IMCC) in reverse merger transaction. Feb 29
Kadimastem Ltd, Annual General Meeting, Mar 21, 2024 Feb 20
Kadimastem to Delist from TASE Feb 19
Less than half of directors are independent Jan 08 See more updates
Kadimastem Ltd (TASE:KDST) signed a letter of intent to acquire NLS Pharmaceutics AG (NasdaqCM:NLSP) in a reverse merger transaction. Jul 30
Kadimastem Ltd (TASE:KDST) signed a letter of intent to acquire NLS Pharmaceutics AG (NasdaqCM:NLSP) in a reverse merger transaction. Jul 29 Kadimastem Ltd (TASE:KDST) entered into a non-binding term sheet to acquire IM Cannabis Corp. (CNSX:IMCC) in reverse merger transaction. Feb 29
Kadimastem Ltd, Annual General Meeting, Mar 21, 2024 Feb 20
Kadimastem to Delist from TASE Feb 19
Less than half of directors are independent Jan 08
Kadimastem Receives Approval of Patent Registration for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in a Third Territory Sep 29
Less than half of directors are independent Apr 27
Kadimastem Ltd Receives Grant for a Total Budget of ILS 10 Million from the Israeli Innovation Authority Mar 06
Kadimastem Ltd announced that it has received ILS 10.000001 million in funding from Ilex Medical Ltd Dec 01
Kadimastem Granted Patent in Israel for the Directed Differentiation of Astrorx for Use in Drug Screening and the Treatment of ALS Mar 11
Kadimastem Ltd. Appoints Asaf Shiloni as CEO Feb 02
New 90-day low: ₪1.94 Jan 14
New 90-day low: ₪2.15 Dec 30
New 90-day high: ₪2.98 Nov 12
New 90-day high: ₪2.97 Oct 27
Kadimastem Ltd announced that it expects to receive ILS 0.72 million in funding Oct 06 Shareholder Returns KDST IL Biotechs IL Market 7D -1.1% 1.1% 3.2% 1Y 109.7% -5.0% 28.5%
See full shareholder returns
Return vs Market: KDST exceeded the IL Market which returned 30% over the past year.
Price Volatility Is KDST's price volatile compared to industry and market? KDST volatility KDST Average Weekly Movement 16.8% Biotechs Industry Average Movement 5.7% Market Average Movement 4.0% 10% most volatile stocks in IL Market 7.2% 10% least volatile stocks in IL Market 2.7%
Stable Share Price: KDST's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: KDST's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.
Show more Kadimastem Ltd Fundamentals Summary How do Kadimastem's earnings and revenue compare to its market cap? KDST fundamental statistics Market cap ₪51.00m Earnings (TTM ) -₪9.72m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) KDST income statement (TTM ) Revenue ₪0 Cost of Revenue ₪0 Gross Profit ₪0 Other Expenses ₪9.72m Earnings -₪9.72m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -2.32 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -83.8%
How did KDST perform over the long term?
See historical performance and comparison
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}
